1. Healthcare

  2. •

    Medical - Equipment & Services
Exactech, Inc.

Exactech, Inc.

EXAC
Exactech, Inc.US flagNASDAQ
49.25
USD
- -
- -
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
TTM
Revenue per Share
7.39
8.13
8.99
10.15
13.13
13.88
14.77
15.68
16.95
17.61
18.09
17.25
18.3
18.51
Basic EPS, GAAP
0.66
0.59
0.68
0.73
0.9
0.65
0.81
0.67
0.96
1.14
1.2
1.05
0.01
0.03
Free Cash Flow per Basic Share
-0.06
-1.87
0.64
1.11
-1.06
0.69
-1.56
-0.32
0.4
0.07
0.97
0.61
-0.06
0.27
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.39
3.94
4.55
4.93
5.8
6.24
6.99
7.56
8.45
9.45
10.46
11.3
11.26
11.96
Tangible Book Value per Share
-0.46
-0.51
-0.46
-0.32
-1.38
8.75
9.05
9.74
10.86
12.39
13.67
14.04
14.92
15.77
Basic Weighted Avg Shares
11
11
11
12
12
13
13
13
13
13
14
14
14
14
Sales/Revenue/Turnover
82
91
102
124
162
177
190
205
224
237
248
242
258
264
Operating Margin (%)
15.06
12.45
13.6
12.05
11.47
8.31
9.66
6.73
9.51
10.09
10.58
9.22
2.96
2.79
Depreciation Expense
4
6
6
7
9
9
11
14
15
16
17
17
18
19
Net Income, GAAP
7
7
8
9
11
8
10
9
13
15
16
15
- -
- -
Effective Tax Rate (%)
35.71
35.07
33.29
35.23
36.82
41.24
42.57
33.69
35.96
31.4
31.66
27.36
96.81
90.8
Profit Margin (%)
8.93
7.26
7.57
7.19
6.86
4.7
5.49
4.3
5.68
6.48
6.64
6.11
0.06
0.18
Working Capital
38
58
48
54
79
74
86
92
99
112
113
115
110
108
LT Debt
7
29
22
9
22
13
42
46
38
34
20
16
20
14
Total Equity
- -
- -
- -
- -
- -
132
145
155
171
192
211
228
234
250
Return on Invested Capital (%)
108.99
39.61
35
56.88
67.96
10.16
6.32
4.65
6.5
7.4
7.74
6.75
0.1
0.26
Return on Capital (%)
17.78
11.13
10.41
12.22
13.35
9.24
9.55
6.87
9.16
10.23
10.42
9.21
0.11
0.31
Return on Common Equity (%)
21.6
16.2
16.17
15.94
16.84
11.02
12.32
9.33
12.09
12.87
12.18
9.78
0.1
0.28

Capital Structure

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
ST Debt
- -
- -
- -
LT Borrowings
16
14
14
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
15
15
Market Capitalization
357
424
471

Working Capital

FRC

•

in mil. unless spec.
Mar'17
Jun'17
Sep'17
Total Current Assets
143
142
143
Cash, Cash Equivalents & STI
11
9
12
Accounts Receivable, Net
59
58
57
Inventories
66
67
70
Total Current Liabilities
35
35
35
Payables & Accruals
33
31
32
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.62%
2.56%
Free Cash Flow
13.65%
164.27%
-109.36%
Net Income, GAAP
-1.26%
-7.41%
-98.9%
Sales/Revenue/Turnover
9.99%
4.71%
6.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
61
61
56
63
242
2016
65
66
60
66
258
2017
69
67
61
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
0.3
0.26
0.2
0.29
1.05
2016
0.31
0.31
0.22
-0.83
0.01
2017
0.32
0.34
0.2
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -

Company Description

APIChat
Sector
Healthcare
Industry
Medical - Equipment & Services
Address
IPO Date
May 30, 1996
CIK
0001844019
Similar Companies
Derma Sciences, Inc. (DSCI)
Hi-Clearance Inc. (1788.TWO)
Revenio Group Oyj (0KFH.L)
Balsm Alofoq Medical Co. (9620.SR)
Hologic, Inc. (0J5Q.L)
Hoshi Iryo-Sanki Co., Ltd. (7634.T)
Business
Exactech, Inc. develops, manufactures, markets, distributes and sells orthopedic implants, related surgical instrumentation and biologic services for joint replacement procedures worldwide. The company offers extremities products including the Equinoxe platform shoulder system for degenerative disease and trauma treatment; knee systems such as Truliant, Triverse and Newton for partial, primary and revision total knee arthroplasty; hip solutions encompassing Alteon HA primary femoral stems, Alteon neck preserving femoral stems, Alteon tapered wedge stems and Spartan hip systems for arthroplasty, reconstruction and fractures; foot and ankle systems featuring the Vantage total ankle system, customizable plates and screws, and patient-specific instrumentation; biologics including Optecure demineralized bone matrix and OpteMx tri-calcium phosphate/hydroxyapatite synthetic bone graft substitutes; spine products for bone and soft tissue regeneration; bone cements such as Cemex Genta with antibiotics and Cemex Fast; spacers including InterSpace hip, knee and shoulder models; and smart technologies comprising the Exactech AI ecosystem, ExactechGPS navigation, Accelerate platelet concentrating system, Ossigen 3D collagen bone matrix, Ossilix calcium phosphate bone cement and AcuDriver automated osteotome system. Exactech markets these products through independent sales agencies, distributors, direct representatives and subsidiaries to hospitals, surgeons and clinics in more than 30 countries, with global offices in Austria, Australia, France, Germany, Italy, Japan, Korea, Spain, Switzerland and the United Kingdom. Founded in 1985 and headquartered in Gainesville, Florida, the company underwent a Chapter 11 reorganization in 2024-2025, culminating in court-confirmed asset sale effective October 31, 2025, to Advita Ortho LLC, a new entity backed by Strategic Value Partners, Stellex Capital Management and Greywolf Capital Management, which acquired substantially all operations, proven product lines, engineering and manufacturing capabilities; the transition includes new CEO Aurelio Sahagun succeeding Darin Johnson.